Q3 2025 Earnings Call Transcript December 10, 2024 Operator: Good afternoon, and welcome to the HealthEquity Third Quarter ...

In addition to holiday celebrations, the month of December typically ushers in a final round of enforcement actions by the U.S. Department of ...

Submissions to Business Briefcase should be emailed to [email protected]. Please write “Business Briefcase” in the subject ...

The IDE study uses the RNS System, which has demonstrated safety and effectiveness of brain-responsive stimulation for treating medically intractable focal onset seizures in people 18 and older, to ...

NYSE:TAK) Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics ...

Dr. Russo's session will delve into the unique mechanism of action of the AVIM therapy and robust body of supporting clinical data. Dr. Russo will detail how AVIM therapy is designed to modulate the ...

Blackstone Police Chief Gregory Gilmore announced a new initiative for individuals with cognitive impairments to help keep ...

KTLA 5 wants you to set sail for adventure aboard the Disney Treasure — the newest ship from Disney Cruise Line! On board, ...

Due to the ongoing strike at Canada Post, many shareholders have not yet received AGM meeting materials. All AGM materials including proxy voting forms can be found on Astra's website at the following ...

Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23 months median Overall Survival from date of ...

When CAA ’21 was enacted, it included a provision that prohibits group health plans and health insurance carriers from ...

ELM-1 is an ongoing, open-label, multicenter Phase 1 trial to investigate the safety and tolerability of odronextamab in patients with CD20+ B-cell malignancies previously treated with CD20-directed ...